Skip to main content
Erschienen in: Der Gynäkologe 9/2009

01.09.2009 | Leitthema

Brustkrebs: die junge Patientin

verfasst von: Dr. D. Varga, A. Wöckel, I. Debatin, R. Kreienberg

Erschienen in: Die Gynäkologie | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Brustkrebs ist das häufigste Malignom der Frau in der Bundesrepublik Deutschland. Etwa 10–12% aller Brustkrebsfälle betreffen Frauen zwischen dem 20. und 35. Lebensjahr. Aufgrund einer Reihe von Faktoren benötigen junge Patientinnen mit Mammakarzinom ein modifiziertes Krankheitsmanagement. Verschiedene Studien kommen zu dem Ergebnis, dass die Diagnose eines Mammakarzinoms in diesem Alter mit einer schlechteren Prognose verbunden ist. Ursache scheint eine veränderte Tumorbiologie bei jungen Patientinnen zu sein. Bei ihnen ist darüber hinaus die Wahrscheinlichkeit höher, dass es sich um eine erbliche Form der Erkrankung handelt. Eine Vorstellung in einem Zentrum für familiären Brustkrebs ist deshalb empfehlenswert. Bei der Therapieentscheidung muss den Lebensumständen der Patientinnen Rechnung getragen werden. In diesem Zusammenhang müssen Nebenwirkungen der Therapien und Fragen zur Reproduktion Berücksichtigung finden.
Literatur
1.
Zurück zum Zitat Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
2.
Zurück zum Zitat El Saghir NS, Seoud M, Khalil MK et al (2006) Effects of young age at presentation on survival in breast cancer. BMC Cancer 6:194CrossRef El Saghir NS, Seoud M, Khalil MK et al (2006) Effects of young age at presentation on survival in breast cancer. BMC Cancer 6:194CrossRef
3.
Zurück zum Zitat Honrado E, Benítez J, Palacios J (2005) The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 18:1305–1320PubMedCrossRef Honrado E, Benítez J, Palacios J (2005) The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 18:1305–1320PubMedCrossRef
4.
Zurück zum Zitat Jatoi I, Proschan MA (2005) Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol 28:289–294PubMedCrossRef Jatoi I, Proschan MA (2005) Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol 28:289–294PubMedCrossRef
5.
Zurück zum Zitat Kroman N, Holtveg H, Wohlfahrt J et al (2004) Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 100:688–693PubMedCrossRef Kroman N, Holtveg H, Wohlfahrt J et al (2004) Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 100:688–693PubMedCrossRef
6.
Zurück zum Zitat Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23:8469–8476PubMedCrossRef Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23:8469–8476PubMedCrossRef
7.
Zurück zum Zitat De Laurentiis M, Cancello G, D’Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53CrossRef De Laurentiis M, Cancello G, D’Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53CrossRef
8.
Zurück zum Zitat LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L et al (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711–1723CrossRef LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L et al (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711–1723CrossRef
9.
Zurück zum Zitat Malone KE, Daling JR, Neal C et al (2000) Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88:1393–1402PubMedCrossRef Malone KE, Daling JR, Neal C et al (2000) Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88:1393–1402PubMedCrossRef
10.
Zurück zum Zitat Mitchell KW, Carey LA, Peppercorn J (2009) Reporting of race and ethnicity in breast cancer research: room for improvement. Breast Cancer Res Treat Mitchell KW, Carey LA, Peppercorn J (2009) Reporting of race and ethnicity in breast cancer research: room for improvement. Breast Cancer Res Treat
11.
Zurück zum Zitat Newman LA, Kuerer HM (2005) Advances in breast conservation therapy. J Clin Oncol 23:1685–1697PubMedCrossRef Newman LA, Kuerer HM (2005) Advances in breast conservation therapy. J Clin Oncol 23:1685–1697PubMedCrossRef
12.
Zurück zum Zitat Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef
13.
Zurück zum Zitat Rakha EA, Elsheikh SE, Aleskandarany MA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302–2310PubMedCrossRef Rakha EA, Elsheikh SE, Aleskandarany MA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302–2310PubMedCrossRef
14.
Zurück zum Zitat Robertson JF, Blamey RW (2003) The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer 39:861–869PubMedCrossRef Robertson JF, Blamey RW (2003) The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer 39:861–869PubMedCrossRef
15.
Zurück zum Zitat Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17PubMedCrossRef Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17PubMedCrossRef
16.
Zurück zum Zitat Ross JS, Hatzis C, Symmans WF et al (2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13:477–493PubMedCrossRef Ross JS, Hatzis C, Symmans WF et al (2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13:477–493PubMedCrossRef
17.
Zurück zum Zitat Rottenberg S, Jaspers JE, Kersbergen A et al (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 105:17079–17084PubMedCrossRef Rottenberg S, Jaspers JE, Kersbergen A et al (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 105:17079–17084PubMedCrossRef
18.
Zurück zum Zitat Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746PubMed Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746PubMed
19.
Zurück zum Zitat SEER Cancer Statistics Review, 1975–2005. SEER NCI SEER Cancer Statistics Review, 1975–2005. SEER NCI
20.
Zurück zum Zitat Tassone P, Tagliaferri P, Perricelli A et al (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285–1291PubMedCrossRef Tassone P, Tagliaferri P, Perricelli A et al (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285–1291PubMedCrossRef
21.
Zurück zum Zitat Yang SH, Yang KH, Li YP et al (2008) Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol 19:1039–1044PubMedCrossRef Yang SH, Yang KH, Li YP et al (2008) Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol 19:1039–1044PubMedCrossRef
Metadaten
Titel
Brustkrebs: die junge Patientin
verfasst von
Dr. D. Varga
A. Wöckel
I. Debatin
R. Kreienberg
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Die Gynäkologie / Ausgabe 9/2009
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI
https://doi.org/10.1007/s00129-009-2358-2

Weitere Artikel der Ausgabe 9/2009

Der Gynäkologe 9/2009 Zur Ausgabe

CME Weiterbildung · Zertifizierte Fortbildung

Das Wochenbett

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.